Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Jun 22 2022 | Cytokinetics Provides Regulatory Update for Omecamtiv Mecarbil Industry News In The News Industry Read More May 20 2022 | Cytokinetics Provides Regulatory Update Related to New Drug Application for Omecamtiv Mecarbil Industry News In The News Industry Read More Apr 28 2022 | U.S. Food and Drug Administration Approves Camzyos™ (mavacamten) for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms Industry News In The News Industry Read More Apr 22 2022 | Request for Proposals (RFP): Quality Improvement Grants to Support Development of Cardiac Amyloid Centers Industry News In The News Industry Read More Apr 1 2022 | ACC, AHA, HFSA Issue Heart Failure Guideline HFSA News Heart Failure Guidelines In The News Journal of Cardiac Failure Press Release Research Read More Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Next page Next › Last page Last »
Jun 22 2022 | Cytokinetics Provides Regulatory Update for Omecamtiv Mecarbil Industry News In The News Industry Read More
May 20 2022 | Cytokinetics Provides Regulatory Update Related to New Drug Application for Omecamtiv Mecarbil Industry News In The News Industry Read More
Apr 28 2022 | U.S. Food and Drug Administration Approves Camzyos™ (mavacamten) for the Treatment of Adults With Symptomatic New York Heart Association Class II-III Obstructive Hypertrophic Cardiomyopathy (HCM) to Improve Functional Capacity and Symptoms Industry News In The News Industry Read More
Apr 22 2022 | Request for Proposals (RFP): Quality Improvement Grants to Support Development of Cardiac Amyloid Centers Industry News In The News Industry Read More
Apr 1 2022 | ACC, AHA, HFSA Issue Heart Failure Guideline HFSA News Heart Failure Guidelines In The News Journal of Cardiac Failure Press Release Research Read More
